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Classic hereditary hemochromatosis is an autosomal recessive disorder caused by mutations in the HFE gene, resulting in increased intestinal iron absorption and iron accumulation in several organs. In the study by Sanchez et al. (2) , Ͼ80% of the Spanish patients with hereditary hemochromatosis were homozygous for the HFE C282Y mutation or compound heterozygotes for the HFE C282Y and H63D mutations.
Although hereditary hemochromatosis has low penetrance in young women, we studied the HFE genotypes of 78 PCOS patients and 43 control subjects characterized in our previous report of increased body iron stores in PCOS (1). Genotyping was conducted by PCR/ restriction fragment-length polymorphism methods using the PmlI and BclI restriction enzymes for the C282Y and H63D mutations, respectively. The ethics committee of the Hospital Ramó n y Cajal approved the study, and informed consent was obtained from all participants.
We did not find homozygosity for the C282Y substitution in HFE in any PCOS patient or control subject. Three patients with PCOS but no control subjects were compound heterozygotes for the C282Y and H63D mutations ( 2 ϭ 1.696, P ϭ 0.552), but their serum ferritin levels were 14, 82, and 113 pmol/l (normal range 11-325), ruling out a condition of iron overload.
Forty-eight of the patients (61.5%) and 24 of the control subjects (55.8%) had one or more mutated alleles of the C282Y and H63D genotype alleles, whereas all other women were homozygous for wild-type alleles of both HFE mutations ( 2 ϭ 0.377, P ϭ 0.539). The HFE mutations studied here did not influence serum ferritin levels when considering PCOS patients and control subjects as a whole ( Finally, a multivariate stepwise linear regression analysis model retained BMI (␤ ϭ 0.263, P ϭ 0.003) and PCOS status (␤ ϭ 0.238, P ϭ 0.007) as predictive variables of serum ferritin levels (R 2 ϭ 0.127, F ϭ 8.557, P Ͻ 0.001), whereas carrier status for C282Y and/or H63D mutations, as well as having oligo/amenorrhea compared with having regular cycles, were excluded as predictors.
In summary, PCOS is not associated with the C282Y and H63D mutations in HFE, and these mutations did not influence serum ferritin levels in our series. As discussed earlier (1), other mechanisms are possibly related to the increase in body iron stores observed in overweight and obese PCOS patients. (A1C) is widely used to assess glycemic control in clinical and research settings, but the precise relationship between A1C and preceding selfmonitored plasma glucose measurements is recognized to be complex. It has been reported that measuring plasma glucose levels in the 120 days before an A1C measurement has a nonuniform effect on the result depending on the time that has elapsed between the glucose level and subsequent A1C measurement (1). Tahara and Shima (2) attempted to model this weighted-average relationship between plasma glucose and A1C by measuring decreases in glucose and corresponding decreases in A1C in patients admitted to the hospital. Their model gives maximum weighting to glucose measurements immediately before the A1C measurement, with the weighting linearly decreasing for glucose measurements further back in time, reaching zero weighting for plasma glucose Ͼ120 days before the A1C.
Treviñ o (3) reported that this weightedaverage relationship leads to an anomalous relationship between the exponential decay rates of glucose (G t ) and A1C. We have reviewed this result and believe that no such anomaly exists. Treviñ o subtracted A1C calculated from the Tahara model (H t ) from "the mean of patientadmission A1C values" (H start ), obtaining the counterintuitive result that a faster decay in blood glucose results in a slower decay in (H start Ϫ H t ). However, this "inverted" decay is likely to be due to subtracting H t from a constant value. His expression for H t is an absolute A1C value, not a change in A1C. An initial value, G s , has been specified for G t , and hence an initial value is implicit in his calculations. Subtracting H t from a constant would not be expected to give a valid A1C estimate.
To verify this conclusion, we simulated a patient with a constant glucose level followed by an exponential decay upon admission to the hospital. During the preadmission time period, the simulated A1C reached a steady state under the constant glucose conditions, which avoided any ambiguity over the initial value (H start ) of A1C. In this simulation, the decay rates of H t then varied in the same way as those for the glucose data, as would be intuitively expected. The use of two initial values by Treviñ o, one for H and one for G, appears to have led to the anomalous result previously reported, rather than any inherent defect in the weighted-average relationship proposed by Tahara and Shima.
Is Pregnancy Outcome Worse in Type 2 Than in Type 1 Diabetic Women?
M ost research on pregestational diabetes has focused on type 1 diabetes, and surprisingly little knowledge exists concerning outcomes of pregnancies of women with type 2 diabetes. A dearth of published data suggest outcomes similar to those of type 1 diabetic women (1,2) , although recent studies report poorer outcomes in women with type 2 diabetes (3-7) .
We retrospectively compared maternal and perinatal outcomes of 93 consecutive singleton pregnancies in women with type 2 diabetes and 532 consecutive singleton pregnancies in women with type 1 diabetes referred to the Diabetes and Pregnancy Unit at University Hospital La Paz from 1984 to 2004.
Women with type 2 diabetes were significantly older ([means Ϯ SD] 31.8 Ϯ 5.5 vs. 29.4 Ϯ 4.7 years, P Ͻ 0.001), were more frequently obese (45.2 vs. 9%, P Ͻ 0.001), and had a shorter duration of diabetes (5.7 Ϯ 6 vs. 11.8 Ϯ 7.1 years, P Ͻ 0.001). The rate of preconceptional care (16.1 vs. 22.6%, P ϭ 0.175) and gestational age at first visit (12.1 Ϯ 6.8 vs. 11.5 Ϯ 6.9 weeks' gestation, P ϭ 0.529) did not differ between type 2 and type 1 diabetic women. Maternal and perinatal outcomes are shown in Table 1 . Insulin requirements and HbA 1c (A1C) were lower during all three trimesters of preg- 
